Program
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Also written as “medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated”, “high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated” and “bivalent enterovirus vaccine (Vero cell), inactivated”.
Its studies are mostly in Hand, Foot and Mouth Disease, led by Sinovac Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 21 open or running | phase 3since Dec 4, 2024 | Sep 15, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2023First study: phase 2 study in Hand, Foot and Mouth DiseaseFirst studyNCT06063057 · 744 enrolled · China
- Dec 4, 2024Phase 3 study in Hand, Foot and Mouth DiseaseNCT06734832 · 8,000 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06734832Hand, Foot and Mouth Disease · China | 3 | Recruiting | Nov 30, 2025 | 8,000 |
| NCT06063057Hand, Foot and Mouth Disease · China | 2 | Completed | Dec 19, 2025 | 744 |
How it is read
Names in the registry
- “low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated”, 1 entry
- “medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated”, 1 entry
- “high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated”, 1 entry
- “bivalent enterovirus vaccine (Vero cell), inactivated”, 1 entry
Conditions, from the studies’ own filings
- Hand, Foot and Mouth Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.